Leaders in Pharmaceutical Business Intelligence (LPBI) Group

 

2014 YEAR-END STATEMENT

by Aviva Lev-Ari, PhD, RN 

Director and Founder, Leaders in Pharmaceutical Business Intelligence

Dear Board Members, Business Community Members, Clients and Team Members

I welcome all addressees to this e-mail to rejoice with us at LEADERS IN PHARMACEUTICAL BUSINESS INTELLIGENCE — AS WE CELEBRATE OUR 2014 as follows:

A.  PHARMACEUTICALINTELLIGENCE.COM —>>Our Open Access Online Scientific Journal

From: “WordPress.com” <donotreply@wordpress.com>

Date: Tue, 30 Dec 2014 01:49:03 +0000

To: <avivalev-ari@alum.berkeley.edu>

Subject: Your 2014 year in blogging [pharmaceuticalintelligence.com]

http://pharmaceuticalintelligence.com/2014/annual-report/

http://pharmaceuticalintelligence.com/2014/12/29/2014-in-review/

The Louvre Museum has 8.5 million visitors per year. This blog was viewed about 230,000 times in 2014. If it were an exhibit at the Louvre Museum, it would take about 10 days for that many people to see it.

The busiest day of the year was December 10th with 2,133 views. The most popular post that day was The History of Hematology and Related Sciences.

In 2014, there were 1,082 new posts, growing the total archive of this blog to 2,609 posts.

 

B.  OUR EVOLUTION and Record accomplishments

 

• In 4/2012 Aviva Launched Leaders in Pharmaceutical Business Intelligence

(LPBI) as an Equity Sharing entity to become a Holding company, initially as

an Electronic Scientific Media entity — The “parmaceuticalintelligence.com” — Open Access Online Scientific Journal

http://pharmaceuticalintelligence.com/

• In 10/2012 Aviva Launched the BioMed e-Series — 15 title e-Books in FIVE

e-Series in Medicine

http://pharmaceuticalintelligence.com/biomed-e-books/

• In 6/2013 we published our first e-Book on Nitric Oxide on Amazon.com,

Kindle edition

http://www.amazon.com/dp/B00DINFFYC 

• In 12/2014 we have SIX READY e-Books in Medicine in QA in the Pipeline

Cardiovascular Diseases: Volumes 2, 3, 4

Genomics Volume 1

Cancer Volume 1

Metabolomics

Plan for 2015: FIVE e-Books in the Pipeline

Cancer Volume 2 – Internal Editor

Genomics Volume 2 – I am interviewing an Editor

CVD Volumes 5, 6

Physiology, Pharmaco-Therapy and Genomics – Larry H Bernstein, MD, Author and Editor, See it in Series E, Volume 3

• In 8/2013 we were approached by ASI, Inc and by ValveCure, Inc. – to assist in Funding Finding. The interactions has led to development of new Intellectual Property. We have BDs assigned to both Start Ups.
• In 9/2013 we were approached by the Chamber of Commerce in Shanghai to organize Scientific Delegations of Patent Holders to meet with Private Investors in China
• Since 4/2013 — Aviva was granted TEN times a Press Passes to cover for the Scientific Media — BioTech Conferences. Her superior Networking skills with Speakers, attendees and VCs is a very important part for building LPBI Network of Business connections

 

C.      ALL LPBI TEAM MEMBERS are of Two types:

 

1.        Expert, Authors, Writers (EAWs) — All are PhDs, MDs, MD/PhDs or 

PharmDs — I INVITE them to JOIN my Team by their publications and

accomplishment in 15 years after earning a PhD, an MD, etc. Exception to this rule is Dr. Irina Robu, less than 15 years since earned her PhD.

http://pharmaceuticalintelligence.com/contributors-biographies/

2.        Business Development Executives (BDs)— Engineers and Engineers with Technical MBAs. All BDs are Technology Execs NONE is a Finance only professional.

Respectively, we do not DEAL only with the Finance aspect of the Business — WE ARE A PROUD SCIENTIFIC  & TECHNOLOGY TEAM — We are not a Finance Team. In Deals with Clients — it is our own technological expertise and accomplishment that advance a deal, the sheer technical KNOWHOW and professional GRAVITAS of each BD which Aviva has cherry picked to join the Team, will be proven to be the key to all our deals.

http://pharmaceuticalintelligence.com/contributors-biographies/business-development-private-equity-investment/

BDs among US

Team Members in Business Development Roles — On Record 12/28/2014:

•   BDs with CV on Line: Dr. Yossi Ezer, Dr. Peter Nelboeck,

Yoel Ezra, Dr. Irina Robu, Dr. Demet Sag (EAW), Dr. Stephen J Williams (Sr.

Editor), Ron Shifron

 

 

D.      OUR 2015 NEW CLIENTS

• QTG
• BioTree
• CPA GROUP in Switzerland
• INSYS in Switzerland

We sign NDAs and CDAs

AFTER 1/15 — Aviva will start to schedule BDs and Presentations on each of the CPA Eight Companies

AFTER 2/15 — Aviva will start  to schedule BDs and Presentations on each of INSYS four Technologies

 

E.      NEW TALENT ACQUISITION

 

• ALL LPBI Team members have looked at Aviva’s Profile on LinkedIn, some  called Aviva directly, as well
• Aviva, has approached them from the Screen of her Profile on LinkedIn, 2-3 out of 20 daily visitors
• Aviva has +5,600 Life Sciences FIRST level connections on LinkedIn, except to 100 Israeli she asked to connect with, ALL THE REST WITHOUT EXCEPTION HAVE REQUESTED HER TO JOIN THEIR NETWORK
• Anyone  who join the Team is “at will” and is looking forward to build a Book of Business with us
• We have ~20 Start Ups as clients and I expect 2015 to be a very active year

Go to

http://pharmaceuticalintelligence.com/vision/ 

• When we engage in Funding Finding we may actually be doing STRATEGY Consulting on Technology Licensing, M&A and Exit or Partnerships
• Focus on Funding, Deals & Partnerships 

http://pharmaceuticalintelligence.com/joint-ventures/ 

1           Corporate Clients for our Services

http://pharmaceuticalintelligence.com/joint-ventures/corporate-clients-for-our-services/ 

2           Funding Cardiovascular Medical Devices Development

http://pharmaceuticalintelligence.com/joint-ventures/funding-cardiovascular-medical-devices-development/ 

3           Funding Biologics Development

http://pharmaceuticalintelligence.com/joint-ventures/funding-biologics-development/ 

4           Funding Diagnostics

http://pharmaceuticalintelligence.com/joint-ventures/funding-diagnostics/ 

5           Funding Partnerships in IP Development

http://pharmaceuticalintelligence.com/joint-ventures/funding-partnerships-in-ip-development/ 

6           M&A and Exit

http://pharmaceuticalintelligence.com/joint-ventures/ma-and-exit/

7           Targeting Penetration in New Markets for High Technology Products

http://pharmaceuticalintelligence.com/joint-ventures/targeting-penetration-in-new-markets-for-high-technology-products/ 

8          Management of Engineering Design of Prototypes Outsourcing

http://pharmaceuticalintelligence.com/joint-ventures/management-of-engineering-design-of-prototypes-outsourcing/

 

F.       DOING BUSINESS WITH LPBI  

 

• In Funding Finding all BDs have access to LPBI’s IT Business Intelligence Database created by Aviva
• In some cases Aviva contact directly the Sources for Introduction of a BD or for Prospecting directly
• We wish to raise $10 Millions for each Start Up with whom we do business with
• Our Finder Fee Agreement is for 10%, 7% is for the BD and 3% is for Aviva, she refers BDs to her contacts and functions as Counsel-at-large on concepts and markets via accessing LPBI’s IT Business Intelligence Database created by Aviva
• All Team members and all Clients will be notifies of ALL new business opportunities and invited to participate

1. All Team members CV and all Clients Profile MUST be on our System – LIVE 24×7 — we operate in the Cloud of WordPress.com
2. All Team members and all Clients — for being connected and up-to-date MUST perform the following:

• FOLLOW by e-mail the Scientific Journal

http://pharmaceuticalintelligence.com 

• BEFRIEND the venture on Facebook

http://www.facebook.com/LeadersInPharmaceuticalBusinessIntelligence 

• FOLLOW the venture on Twitter

http://twitter.com/pharma_BI 

• JOIN LPBI LinkedIn Group

http://www.linkedin.com/groups?gid=4346921&trk=hb_side_g

 

 

 

HAPPY NEW YEAR TO ALL

 

We are looking forward to a VERY prosperous 2015 — The Year of Biotech,

Pharma, BioMed

 

I thank all the Team memberes that led projects and contributed to all the milestones achieved in 2014.

 

Aviva Lev-Ari, PhD, RN

1-617-244-4024

University of California, Berkeley, PhD’83

avivalev-ari@alum.berkeley.edu

BioMed e-Books Series – Editor-in-Chief

http://pharmaceuticalintelligence.com/biomed-e-books/

Founder & Director

Leaders in Pharmaceutical Business Intelligence

http://pharmaceuticalintelligence.com